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Introduction
Gamma-glutamyl transferase (GGT) is the en-
zyme responsible for the extracellular catabolism of 
glutathione, the main thiol antioxidant in mamma-
lian cells [1]. The GGT is located on membranes of 
cells with high secretory or absorptive activitiy, es-
pecially in liver, kidney, pancreas, intestine, heart, 
brain and prostate [2]. Serum GGT activity is affected 
by genetic and environmental factors [3]. GGT is a 
second-generation enzymatic liver function test that 
was used initially as a sensitive marker of hepatic 
inflammation.
Changes in GGT concentrations have been report-
ed in a wide variety of clinical conditions including 
pancreatic disease, myocardial infarction, renal fail-
ure, chronic obstructive pulmonary disease, diabetes 
and alcoholism [4–6]. Alterations in serum GGT con-
centrations are also found in patients who are taking 
medications such as phenytoin and barbiturates as 
well as in people with increased meat intake [7]. 
In addition to its diagnostic uses, serum GGT 
has substantial epidemiologic significance [8]. It is 
known that the GGT levels rise, independently of 
alcohol consumption, with age and other pathologi-
cal conditions, such as diabetes [9], obesity [10] and 
congestive heart failure [9]. Different studies have 
shown a strong positive association between serum 
GGT level and body mass index, alcohol use, smok-
ing, total lipoprotein and HDL concentration, serum 
cholesterol, uric acid, serum triglycerides, heart rate, 
systolic and diastolic blood pressure, antihyperten-
sive medication, preexisting ischemic heart disease, 
diabetes mellitus, blood glucose, use of oral contra-
ceptives and menopause. In the same time, pregnant 
women have lower values of GGT [11, 12].
This review discusses the biochemical and meta-
bolic properties of GGT, its applicability as a marker 
of fatty liver and analyse its possible role in the patho-
genesis of the metabolic syndrome and the type 2 dia-
betes mellitus as well as subsequent cardiovascular 
disease (CVD). We have also discussed the treatment 
strategies in fatty liver disease and the management 
of the associated risk factors.
GGT as a marker of liver disease 
Serum GGT is signifi cantly increased in hepato-
biliary diseases, with the highest concentrations reg-
istered in cholestatic conditions [8]. GGT was inves-
tigated and adopted as a liver function test or liver 
enzyme in the 1960s and 1970s. It is a sensitive test, 
being abnormal in most patients with liver disease re-
gardless of cause, although higher values are found in 
patients with cholestasis.
Early clinical studies showed a high prevalence 
of abnormal GGT in patients with primary or sec-
ondary liver cancer. HCC-associated GGT could be 
positive in patients with hepatoma who had normal 
a-fetoprotein. GGT isoenzymes may be useful in de-
tecting, monitoring or even predicting HCC, but so 
far there are not suffi cient results available to be con-
fi dent about the claims of its high sensitivity. 
Liver steatosis
Excess deposition of fat in liver, usually termed 
nonalcoholic fatty liver disease (NAFLD), is closely 
associated with elevated serum GGT. The main inter-
est in relation to GGT is the fact that the condition is 
similar to alcoholic liver disease. In the same time 
the affected population does not consume alcohol 
regulary. In such patients are frequently determined 
the epidemiological associations between GGT and 
obesity, insulin resistance, diabetes, and fatty liver. 
[13–15].
Hepatic steatosis and elevated serum GGT asso-
ciation is not completely clear, but several possible 
explanations have been proposed by Ortega et al. 
[16]. For example, fatty liver could cause hepatocel-
lular damage that would simulate the synthesis of 
GGT. Alternatively, the excess fat in liver could en-
hance oxidative stress, leading to the overconsump-
tion of glutathione with a compensatory increase in 
GGT synthesis. Finally, a higher GGT production 
could be secondary to a low grade hepatic infl amma-
tion induced by hepatic steatosis. 
Metabolic disturbances
The Adult Treatment Panel III of the National 
Cholesterol Education Program (NCEP)  proposed 
a defi nition of the metabolic syndrome which incor-
porates thresholds for fi ve easily measured variables 
linked to insulin resistance: waist circumference, 
triglyceride level, HDL cholesterol level, fasting 
plasma glucose level and arterial pressure [17]. There 
is growing evidence that the liver, which is the pri-
mary source of circulating GGT, is a key target or-
gan in the development of the metabolic syndrome. 
These interrelations between serum GGT, obesity, 
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other metabolic disturbances, such as glycemic disor-
der, hypertriglyceridemia and low HDL cholesterol, 
suggest that that the elevated GGT levels can help in 
the prediction of the development of metabolic syn-
drome as well as the type II diabetes mellitus. Higher 
GGT levels in obese persons, particularly those with 
abdominal obesity, is another important association 
between GGT and metabolic syndrome. This associa-
tion is further strengthened by an existent correlation 
between GGT and arterial hypertension. Therefore, it 
has been demonstrated that practically all major com-
ponents of the metabolic syndrome correlate with the 
higher serum GGT activity. 
Cardiovascular diseases
Serum GGT activity level correlates with the risk 
of fatal events in patients with chronic forms of coro-
nary heart disease, congestive heart failure as well as 
both ischemic and hemorrhagic stroke. This is equal-
ly true for both sexes, with a clear enzyme concen-
tration-cardiovascular risk relationship. The stronger 
prognostic signifi cance of GGT was determined in 
younger persons. In the same time the mechanism of 
association between GGT and cardiovascular risk is 
not yet clear. Although, the mechanism underlying the 
above associations remains largely unknown, it can be 
supposed that the serum GGT activity might be asso-
ciated with cardiovascular risk through a mechanism 
related to oxidative stress: many experimental studies 
have shown that GGT plays an important role in anti-
oxidant defense systems at cellular level [8, 18]. 
Moreover, dietary heme iron was positively as-
sociated with serum GGT concentrations, whereas 
most dietary antioxidants, especially vitamin C and 
beta-carotene, were inversely associated with serum 
GGT activity [7].
Although there is no doubt considering the use 
of GGT as an index of liver function, there are now 
some indications of the direct involvement of GGT 
having in the atherosclerotic plaque formation. [19]
It has been suggested recently that GGT may have a 
role in the pathogenesis of atherosclerosis: GGT ac-
tivity has been detected in atheromatous plaques of 
carotid and coronary arteries, and it has been shown 
that glutathione hydrolysis by GGT can trigger iron-
catalysed low-density lipoprotein (LDL) oxidation 
[20], as well as production of reactive oxygen spe-
cies [21]. These events are known to play a central 
role in the evolution of atherosclerosis: formation of 
the fibrous cap [22], apoptosis of cellular elements 
of the lesion [23], plaque erosion and rupture [24], 
enhanced platelet aggregation and thrombosis.
The possible role of GGT in the atherosclerotic 
process suggests that its predictive value is at least 
partly independent of self-reported alcohol consump-
tion. On the other hand, alcohol consumption has 
been confi rmed to have a protective effect against 
myocardial infarction [25].
However, because of its availability as well as 
low screening costs, higher than expected GGT lev-
els in otherwise healthy individuals suggest a more 
detailed patient’s examination. The following therapy 
can eventually prevent cardiac-related events and 
deaths in the future [26].
Conclusions
As has been shown in epidemiological studies, 
GGT seems to be an appropriate marker of fatty liver 
disease, if known factors that can cause a GGT eleva-
tion have been addressed properly (e.g alcohol con-
sumption and hepatitis B and C infections). 
However, in the upper reference range, GGT has 
been found to be a strong independent biomarker 
for the metabolic syndrome (insulin resistance syn-
drome), which is associated with a cascade of abnor-
malities in the thiol redox system. GGT is also an 
independent risk marker for the development of car-
diovascular disease. It correlates positively with age, 
sex, triglycerides, blood pressure, body mass index, 
low-density lipoprotein cholesterol, fasting glucose, 
ethanol ingestion, and smoking – well known cardio-
vascular risk factors. 
Further academic studies will need to be done to 
evaluate GGT’s overall importance, especially as an 
independent risk factor, that can be used for predict-
ing the development of the metabolic syndrome and 
cardiovascular diseases.
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Abstract 
Gamma-glutamyltransferase is an established liver 
function test and a sensitive marker of hepatic inflammation. 
Recent studies have focused increasing attention on the 
usefulness of GGT as a predictor of cardiovascular disease. 
As a result, identifying higher than expected GGT levels 
should alert the physician to study patients more detailed, 
with the hopeful outcome of preventing unnecessary 
cardiac-related events and deaths in future years.
Rezumat
Gamma-glutamiltransferaza (GGT) se consideră ca 
un test funcţional hepatic şi marker sensibil al infl amaţiei 
hepatice. Studiile recente au atenţionat privind utilitatea 
GGT ca fi ind factor predicator al patologiei cardiovasculare. 
Determinarea nivelului ridicat al GGT impune studierea 
detailată a pacientului cu scopul prevenirii evenimentelor 
cardiovasculare şi mortalităţii în anii succesivi.
Резюме 
Гамма-глутамилтрансфераза (ГГТ) является при-
знанным печёночным тестом и чувствительным 
маркером печеночного воспаления. В последних ис-
следованиях все большее внимание было сосредото-
чено на использовании ГГТ как предиктора сердечно-
сосудистых заболеваний. Таким образом, определение 
повышенного уровня ГГТ должно побудить врача для 
детального исследования пациента с целью предотвра-
щения развития сердечно-сосудистых осложнений и 
смерти в последующие годы.
